Company: NCEL
Filing Date: 2025-10-24
Form Type: POS AM
Source: 0001213900-25-102149
Chunk: 72

Company: NewcelX Ltd.
Filing Date: 2025-10-24
Form: POS AM
Chunk 72
---
 sell to the Selling
Shareholder, up to $25.0 million of the Common Shares, subject to certain conditions and limitations set forth therein.

<div align='center'>II-3</div>

Upon the initial satisfaction
of the conditions to the Selling Shareholder’s obligation to purchase Common Shares set forth in the ELOC Purchase Agreement (the
“Commencement”), including that a registration statement registering the resale by the Investor of the Common Shares under
the Securities Act that may be sold to it by us under the ELOC Purchase Agreement is declared effective and a final prospectus relating
thereto is filed with the SEC, the Company will have the right, but not the obligation, from time-to-time to its sole discretion until
the first day of the month next following the 36-month period from and after Commencement, to direct Selling Shareholder to purchase up
to a specified maximum amount of Common Shares as set forth in the ELOC Purchase Agreement by delivering written notice to the Selling
Shareholder prior to the commencement of trading on any trading day. The purchase price of the Common Shares that the Company elects to
sell to the Selling Shareholder pursuant to the ELOC Purchase Agreement will be 95% of the volume-weighted average price of the Common
Shares during the applicable purchase date on which the Company has timely delivered written notice to the Selling Shareholder directing
it to purchase Common Shares under the Purchase Agreement.

In connection with the execution
of the ELOC Purchase Agreement, the Company agreed to issue a pre-funded warrant (the “Pre-Funded Warrant”), to purchase $250,000
in Common Shares to the Selling Shareholder as consideration for its irrevocable commitment to purchase the Common Shares upon the terms
and subject to the satisfaction of the conditions set forth in the ELOC Purchase Agreement.

Item 8. Exhibits and Financial Statement Schedules

Exhibits:

| Exhibit Number 
 2.1            
 2.2            |     | Exhibit Description                                                                                                                                                                                                                                                                                
 Agreement and Plan of Merger, dated as of November 4, 2024, by and among NLS Pharmaceutics Ltd., NLS Pharmaceutics (Israel) Ltd. and Kadimastem Ltd. (included as Annex A to the proxy statement/prospectus on Registration Statement on Form F-4 filed on September 3, 2025).                     
 Amendment No. 1 to Agreement and Plan of Merger, dated as of January 30, 2025, by